K
Kernal Biologics
Creates mRNA therapies that instruct specific cells on how to make their own medicine
About Kernal Biologics
Kernal Biologics, based in Cambridge, MA, specializes in developing onco-selective mRNA therapeutics. The company operates in the biotechnology sector, focusing on creating advanced treatments for cancer and infectious diseases like COVID-19. Kernal Biologics serves healthcare providers, research institutions, and pharmaceutical companies. Its business model revolves around leveraging proprietary design and manufacturing processes to produce mRNA therapies that evade RNA sensors and enable cell-specific therapeutic protein expression. This approach aims to make treatments more effective, tolerable, and affordable. Revenue is generated through partnerships, grants, and sales of its mRNA platforms and therapies. The company has received multiple awards, including Amgen's Golden Ticket, and is recognized for its innovative use of synthetic biology and deep learning algorithms to enhance mRNA design.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2016
- Headquarters
- Cambridge, United States
- Employees
- 22
- Open positions
- 2
- Dealroom signal
- 89.4/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Genetics and genomics, Spinout, Biotech and Pharma, mRNA Medicines, YC S20, proteomics, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
News
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANT✓Other financing | Oct 2025 | — | — | Advanced Research Projects Agency for Health - ARPA-H | ↗ |
| SERIES A✓Equity / VC | Jul 2022 | $25M | $100M | Civilization Ventures · HBM Genomics · Amino Collective · Hummingbird Ventures | ↗ |
Growth signals
Latest recorded traffic for Kernal Biologics is 3.7K monthly website visits, up 105.6% over the last three months. Kernal Biologics's team grew 57.1% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Kernal Biologics in the Cambridge ecosystem
The Kernal Biologics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed4 investors entered at this stage
Boeing
ISS National Lab
Y Combinator
Advanced Research Projects Agency for Health - ARPA-H
Series A6 investors entered at this stage
Outsized Ventures
Hummingbird Ventures
Civilization Ventures
HBM Genomics
Amino Collective
Amgen Ventures
Other known investors16 additional known investors
Harvard University
Massachusetts Institute of Technology
MassChallenge
Big Bang Ventures
Bluelotus
Calm Ventures
DO Venture Partners
FoundersX Ventures
frank malek
Helen Liang
HOF Capital
Luminous Ventures- MVMCMA Ventures
Scale Asia Ventures
SymBiosis
Wally Wang
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Kernal Biologics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Kernal Biologics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









